Back to All Combinations

RAS/BRAF Wild-Type (Left)

Good Prognosis
25.00% Prevalence Level 1 RAS Pathway
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
KRAS NRAS BRAF
Treatment Implications

Best anti-EGFR candidates. PARADIGM showed superiority vs bevacizumab.

Recommended Treatments
FOLFOX + Panitumumab
FOLFIRI + Cetuximab
Treatments to Avoid

No specific contraindications noted

Study References

PARADIGM, FIRE-3

Key Statistics
25.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Left-sided + RAS WT = anti-EGFR preferred.
Information

Category: RAS Pathway

Evidence Level: Level 1

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.